Targeted Degradation of CDK2: A New Strategy for Overcoming Cyclin E-Driven Cancers

Cyclin-dependent kinase 2 (CDK2) has emerged as a critical oncogenic driver in cancers characterized by cyclin E amplification and resistance to existing cell-cycle therapies. A recent patent disclosure describes heterobifunctional degraders that selectively induce CDK degradation by recruiting E3 ligases. By eliminating rather than inhibiting CDK2, these compounds offer a promising approach to suppress tumor proliferation and overcome therapeutic resistance in cyclin E-dependent malignancies.